| CPC A61K 31/519 (2013.01) [A61K 31/203 (2013.01); A61K 31/381 (2013.01); A61K 31/506 (2013.01); A61K 33/36 (2013.01); A61P 35/00 (2018.01); C07K 16/2827 (2013.01)] | 21 Claims |
|
1. A method of treating a disease or disorder mediated by dysregulated cyclin-dependent kinase 4/6 (CDK4/6) activity, in a subject in need thereof, or a method of reducing the activity of CDK4/6 in a cell, either in vivo or in vitro,
comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effective amount of one or more peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) inhibitors, or a pharmaceutically acceptable salt or salts thereof.
|